Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice

Title

Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice

Content

Lunit (KRX:328130), a Seoul-based provider of AI for cancer diagnostics and precision oncology, announced at the Society of Breast Imaging (SBI) Annual Symposium on April 16, 2026 that its AI-powered breast cancer ecosystem has crossed 330+ screening sites across the Americas, supporting approximately one million screening mammograms annually. The announcement spotlights Lexington Clinic, Central Kentucky's largest physician-owned multi-specialty medical group (350+ providers), as a flagship deployment partner. Lexington Clinic has implemented Lunit's complete breast cancer ecosystem end-to-end: Lunit INSIGHT Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT) detection; Volpara Analytics and Volpara Live for quality optimization; Volpara Scorecard for volumetric breast density; Risk Pathways for risk assessment integrated into clinical workflows; and Patient Hub for mammography tracking. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient," said Angie Hall, Breast Center Manager at Lexington Clinic. Adoption velocity has shifted from evaluation to enterprise-wide implementation. "Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption—where AI is delivering value in routine practice," said Craig Hadfield, CEO of Lunit International. At Radiology Consultants of Iowa (RCI), one of Iowa's largest radiology groups, Lunit INSIGHT DBT has been embedded in routine clinical workflows for six months. "After six months of using AI in our daily workflow, it's become part of how we read. It gives us added confidence—especially in subtle cases—and helps ensure we don't miss what matters most," said Dr. Robert J. Dolan, breast imaging specialist at RCI. The technical architecture combines Lunit's INSIGHT inference engine with the Volpara Analytics platform acquired in 2024, providing risk, detection, and quality scoring in a single integrated workflow. FDA clearance of Version 1.2 of Lunit's 3D mammography algorithm at SBI 2026 introduces current-prior comparison (CPC) across the current exam and up to two priors, three selectable operating thresholds for sensitivity/specificity trade-offs, and direct access to Volpara Scorecard density measures alongside AI scores. Operationally, Lunit supports 10,000+ medical sites across 65+ countries. The Americas enterprise footprint (330+ screening sites, ~1M annual mammograms) represents one of the largest commercial deployments of breast imaging AI globally, with the Lexington Clinic partnership serving as proof point for end-to-end suite adoption rather than point solutions. Future direction per CEO Hadfield: deepening current-prior comparison capabilities, expanding DBT compatibility, and broadening the integrated ecosystem into adjacent cancer care workflows beyond screening into diagnosis and treatment planning.